Ellex – a world leader in medical technologies for the diagnosis and treatment of eye disease – has secured the Conformité Européenne (CE Mark) for its proprietary Retinal Rejuvenation Therapy (2RT) laser treatment of early Age-related Macular Degeneration (AMD).
The leading cause of blindness in the developed world, AMD, is a chronic eye disease that can result in vision loss. There are no other approved treatments for the early form of AMD. Current treatment options are restricted to targeting the late form of the disease, Wet AMD, which only accounts for approximately 10 per cent of all people with the disease. Another estimated one in 12 patients develop geographic atrophy with central blindness. This treatment provides a minimally invasive option for early and intermediate AMD patients to try and delay the onset of late stage complications.
Ellex CEO Tom Spurling said the CE Mark would allow a limited rollout of the 2RT in Europe, Australia, New Zealand, South East Asia, the Middle East and South America.
“This is a necessary step in validating, and expanding upon, the clinical findings we have for 2RT, and will ultimately support a wider roll out of the product and future growth,” Mr. Spurling said.
